During Introduction of Mammography Screening Analysis of Three Tumor Size Intervals in Screened and Post-Screened Periods Clarified the Short and Long Term Efficacy of Screening

Roland B Sennerstam*
Department of Oncology and Pathology Karolinska Hospital and Karolinska Institutet Stockholm, Sweden

Keywords: Mammography screening; Post-screening effect; Tumor size; Molecular profiles; Death rate; Over diagnosis

Abstract

The present study focused on mammography screening during two periods representing 2 years (1991) to 8 years (1997/98) after the introduction of screening in 1989 in the Stockholm Gotland County, Sweden for women aged 50-69 years. Subjects were sorted by age, as younger (<50 years) unscreened women, screening women aged 50-69 years and analyzed in two decades between 50-69 years and 60-69 years respectively, and unscreened women of ≥ 70 years. Tumor size was compared with an unscreened cohort from 1987, 2 years before screening was introduced. Resolution was increased by focusing on three tumor-size intervals instead of mean tumor size, which showed a tending reduction in tumors ≥ 20 mm for women diagnosed with breast cancer aged 50-59 years in the 1991 sample but a significant decline for women aged 60-69 years having attended two screening tests. After 8 years of biennial screening (1997/98) patients with tumors size > 10 mm at diagnosis had significantly increased, and tumors ≥ 20 mm declined significantly–most clearly among 60-69-year-old women after attending up to five screening tests. A transient increase in tumor sized 10 mm to 20 mm was seen due to the stepwise-altered distribution in size. Women in the two unscreened age groups <50 years and ≥ 70 years, were compared with screened women aged 60-69 (1997/98) according to tumor size, genomic instability, proliferation index, lymph node metastases, cyclin-A and ki67, alteration in breast tumor stage I and stage IIB and survival rate. In all parameters except ki67, only in relation to unscreened women <50 years old showed a significant reduction. A post-screening effect was also found for women aged 70-79 years with tumors size ≥ 20 mm still being reduced compared with controls and the tumors ≤10mm decreasing significantly to the control level.

Introduction

Mammography screening has been the subject of debate ever since it was first introduced. A follow-up data on breast cancer incidence in five countries and three continents after introduction of general screening revealed an increase of breast cancer incidence of 52% [1,2]. The similar phenomenon has been reported from Sweden [3,4]. A reduction in mortality by 31% and 25% decline in the rate of tumor stage II or more advanced breast cancer were found in two Swedish counties between the start of screening and a 7years of follow-up of about 165000-screened women [5]. Efficiency of screening by age showed a smaller positive effect in women aged 40-49 compared with older women [6]. Furthermore, data from 1972–2009 show breast cancer mortality rates decreased from 68.4 to 42.8 per 100,000 women and continue to decline in 14 of the 21 counties in Sweden [7]. In the beginning of the 1970s, the first counties in Sweden started to invite women to mammography screenings. During the following 23 years, the rest of the counties planned and introduced general screening. A recent report describes 18 years follow-up of mortality in breast cancer during this introduction period. Counties that first introduced screening programs during 1974-1978 had no improvement in survival and during 1986-1987, mortality increased with 12%. After 1987, the results began to improve. In the follow-up of the cohorts screened from 1987–1988, mortality decreased by 5% (p<0.01); among breast cancer patients diagnosed from 1989 –1990, mortality was reduced by 8% (p<0.01) [7]. Survival advantage for women with screen-detected tumors has continued to be reported in studies the last decade [8–10]. The early data during the introduction period of screening may reflect the initial effort to get the technology in place, assistants trained and logistics working.

A follow up of a well-screened population in Rhode Island, USA over four time periods diagnosed between 1987 and 2008 revealed statistically significant improvements in reduction of mean cancer size, more favorable pathologic grade, increased breast-conserving surgery and decline in mortality [11]. Other studies suggest that some smaller tumors might not have come to a clinical stage during the woman’s life time, which evokes a debate about overdiagnosis [1,12,13]. An early study reported increased Stage II-IV breast tumors to be found in a study group during the first 3–4 years after introduction of screening but not in the control group, indicating a spontaneous regression of some breast tumors [14]. A proposed natural history of breast cancer includes the idea that some tumors regress spontaneously [15]; such

*Corresponding author: Roland B Sennerstam, Department of Oncology and Pathology Karolinska Hospital and Karolinska Institutet Stockholm, Sweden, Tel: +46 (0) 707810201; Fax: 0046 8 331 696; E-mail: roland.sennerstam@ki.se

Received June 12, 2013; Accepted June 28, 2013; Published July 01, 2013
Copyright: © 2013 Sennerstam RB. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
results may be considered false-positive cases [16]. Analyzing 10-year survival data in almost 20,000 women aged 50–65 years in West Midlands region UK showed that a combination of lead time with tumor mean size and lymph node status in 10 categories could explain 97% of survival advantage in favor of screened-detected versus symptomatically diagnosed breast cancers. Only a small proportion remained to be explained by length bias and overdiagnosis [17].

Lately, age group in the Stockholm Gotland area has extended mammography screening; by 2005, it included women as young as 40 years old, and in 2012, older women up to 74 years of age were included. Guideline programs for mammography screening, type of organization and methods to detect breast cancer from four countries on two continents in service in 1995 (i.e., contemporary to our study period) are shown in Table 1 [18]. The comparison shows that Sweden was well organized in dedicated mammography screening centers organized in line with a common centralized system. The digital mammography technique was introduced in the Stockholm Gotland area in the years 2006 to 2008.

Because some findings from the introduction period of mammography are not clearly understood, this report follows alterations in screening three tumor-size intervals and molecular profiles [19] to compare the unscreened and screened women diagnosed with breast cancer. The post-screening period is also included, which may provide insights to evaluate the overall benefits of mammography screening over time and changes in progressive improvements.

**Materials and Methods**

To reflect the first decade after introduction of mammography screening in 1989 in the Stockholm-Gotland area, cytotoxicological parameters and survival data was analyzed 2 and 8 years later. Two consecutive retrospective samples of breast cancer patients from 1991 (n=519) and 1997/98 (n=345) were examined at the department of Oncology and Pathology, Karolinska University Hospital, Sweden. All patients were treated by either quadrantectomy or wide excision and no wire-localization of small tumors was used. Diagnoses were confirmed after radiography by fine needle biopsy before surgery. The few DCIS found were excluded. The two tumor samples were analyzed for tumor size, proliferation index (PI), including S-phase+G2-phase, and genomic instability reflected as Stemline-Scatter-Index (SSI) (see below). Axillary lymph node metastases were investigated after excision for tumor size, proliferation index (PI), including S-phase+G2-phase, and genomic instability reflected as Stemline-Scatter-Index (SSI) (see below). Axillary lymph node metastases were investigated after excision for the axillary tumor. The use of sentinel nodes was not in practice at this time. Tumor stages I and IIB were ascertained. Cyclin-A and K67 testing were in use only in the 1997/98 sample. DNA-image analysis procedures were done at about in time of diagnosis. One tumor sample from the unscreened period in 1987 was used to compare tumor size with the two screened groups. A number of 445 consecutive breast tumors from 1987, of which 400 had information on tumor size, were selected as controls. We used three tumor size intervals (≤10 mm 10–20 and >20 mm) to reflect alterations in screening effect. Data on deaths due to breast cancer and other causes were retrieved from the Swedish Cause of Death Register. Permission to analyze the samples from clinical patient data was obtained by the Ethical Committee Nord, Karolinska Institutet (2010/34-31/1).

**Feulgen staining**

To examine genomic instability and proliferation activity the DNA parameters in Feulgen-stained tumor nuclei were used. Nuclear DNA content was measured by image cytometry in Feulgen-stained cell nuclei mainly from imprints and some on 8 µm histological sections from the primary breast adenocarcinoma. A pathologist identified single tumor cells; 200 cells per slide were analyzed. Materials were rehydrated in an ethanol series and hydrolysis in one batch of 5 M HCL at 22°C for 60 min. Specimens were then rinsed in distilled water and stained with Schiff reagent at 22°C for 90 min. Normal lymphocyte cells were used as an internal diploid DNA standard (2C). The cells were washed three times in sulfurous acid (10 ml Na2S2O7). Stained cells were then measured in a computer assisted image-analysis system based on an axioscope (Zeiss, Baden-Württemberg, Germany), equipped with an immersion plan-objective (40/0.95; Nikon, Tokyo, Japan) and a CCD camera (Nikon).

**Stemline-scatter-index (SSI)**

In several reports, we used a large-scale estimation for genomic instability and proliferative activity [20], based on parameters from Feulgen-DNA stained nuclei. The parameters combined are the coefficient of variation for the G1 peak (CV) of tumor DNA stemlines (D1) and DNA content values in the S-phase fraction (SPF) for each patient, plus the percentage of cells with DNA content above the G1 DNA level (exceeding G1 rate, ExG1). Thus, the Stemline-Scatter-Index (SSI) includes G1 CV + SPF + ExG1 all expressed in percentages. In previous reports, we used the cut-point value of SSI>8.8% to differentiate between tumors representing significantly scattered DNA histograms (SSI>8.8%) and those with insignificantly scattered ones (SSI ≤ 8.8%). Breast carcinoma with a SSI ≤ 8.8% were classified as genomic-stable and those with a SSI>8.8% as genomic-unstable. However, as increased genomic instability and proliferative activity represent a continuum a cut-point is a somewhat artificial for classifying tumors.

### Table 1: Guidelines in four countries 1995.

<table>
<thead>
<tr>
<th>Countries compared</th>
<th>First national program</th>
<th>Age group screened (years)</th>
<th>Time interval between MM (years)</th>
<th>Detection method</th>
<th>Organized around the country</th>
<th>Type of MM screening center</th>
<th>% target population within screening program</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sweden</td>
<td>1986</td>
<td>50-69</td>
<td>2</td>
<td>MM</td>
<td>Partially centralized</td>
<td>DMC</td>
<td>100%</td>
</tr>
<tr>
<td>Canada</td>
<td>1988</td>
<td>50-69</td>
<td>2</td>
<td>MM CBE BSE</td>
<td>De-centralized</td>
<td>DMC</td>
<td>&lt; 25%</td>
</tr>
<tr>
<td>United States</td>
<td>1991</td>
<td>40-50</td>
<td>1-2</td>
<td>MM CBE BSE</td>
<td>Partially central-ized</td>
<td>DMC M</td>
<td>20-50%</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>1988</td>
<td>50-64</td>
<td>3</td>
<td>MM</td>
<td>Partially central-ized</td>
<td>DMC M</td>
<td>100%</td>
</tr>
</tbody>
</table>

First national mammography screening programs for four countries on two continents are compared for the period of our study, including initial years, target age groups, time intervals between screenings, and type of detection (MM, mammography screening; CBE, clinical breast examination; BSE, breast self-examination). Screening center administrations that were partly centralized were administrated regionally, guided by national policies but with regional funding and administration. Types of facilities were DMC, dedicated mammography screening center, GR, general radiology department; M, mobile unit (from ref. 12).
Immunohistochemistry

Tumor samples were fixed in 4% phosphate buffered formaldehyde directly after operation and paraffin embedded. From each specimen, contiguous 4µm sections were prepared and used on HE staining and immunohistochemistry. Sections were deparaffinized with xylene, rehydrated by a graded alcohol series and microwaved at 500 W for 2 x 5 min in 10 mM citrate buffer (pH 6.0). After rinsing in Tris-buffered saline (TBS, pH 7.6), sections were treated with 3% hydrogen peroxide in methanol to exhaust endogenous peroxidase activity followed by normal horse serum (1:20 dilution) in 0.1 M PBS (pH 6.0), and the incubated overnight with the monoclonal primary antibodies diluted in 1 % (wt/vol) bovine serum albumin (BSA) and visualized by standard avidin-biotin-peroxidase complex technique (Vector Laboratories, Burlingame, CA). Counterstaining was performed with Mayer’s hematoxylin. The antibodies used were MIB-1 (antibody against the nuclear proliferation associated antigen Ki67, Immunotech S.A., Marseille, France) dilution 1:150; NCL-cyclin A ( Cyclin A monoclonal antibody, Novocastra Laboratories Ltd, Newcastle upon Tyne, UK; dilution 1:100). Only distinct nuclear staining was accepted as a positive reaction. All cells with simultaneous nuclear and cytoplasmic cyclin A staining were regarded as positive for cyclin A*. 

Lymph Node Metastasis

In this study, the fraction (0−1) of axillary lymph node metastases (ALNM) was used in place of counted positive glands (i.e., where cancer cells were found). In 1991 cohort yielded 519 patients from whom 303 surgical specimens were taken (58%). Lymph node metastases (ALNM+ ) were observed in 124 patients (24%). The mean number of lymph nodes counted per patient in this group was 8.9 ± 4.2. Among lymph node negative axillary surgical extractions (ALNM−), the mean number of counted glands was 8.4 ± 3.6 (n=179). From the 1997/98 cohort, 218 of 354 (63%) lymph node axillary extractions were done and 76 (22%) were ALNM+. The mean number of node counted in the ALNM+ group was 9.4 ± 3.6. In the negative lymph node group (ALNM−) the mean number of nodes counted was10.5 ± 43.6 (n=139). No statistical difference was found between mean counted nodes in the ALNM+ and ALNM− groups in either patient sample, which justified use of ALNM fractions. In estimating tumor stages I and IIB, only patients with ALNM+ findings were included (TNM staging system AJCC-6). As only lymph node classification, N1 (1-3 positive nodes) patients with ALNM+ findings were included (TNM staging system). Counterstaining was performed with Mayer’s hematoxylin. The antibodies used were MIB-1 (antibody against the nuclear proliferation associated antigen Ki67, Immunotech S.A., Marseille, France) dilution 1:150; NCL-cyclin A ( Cyclin A monoclonal antibody, Novocastra Laboratories Ltd, Newcastle upon Tyne, UK; dilution 1:100). Only distinct nuclear staining was accepted as a positive reaction. All cells with simultaneous nuclear and cytoplasmic cyclin A staining were regarded as positive for cyclin A*.

Statistical Analysis

Statistical calculations were performed using the STATISTICA software package (StatSoft, Inc., Tulsa, OK, USA). Statistical significance for categorical variables was calculated using the chi square test and an independent t-test was used for continuous ones. Linear regression was performed for the correlation test. Statistical significance was assumed if p<0.05.

Results

By analyzing two samples with 8 year’s difference within the first decade after introduction of mammography screening, the effect of screening can be followed step by step. The individual patients diagnosed with breast cancer in the sample from 1997/98 were involved in the screening for 8 years at most; and the patients from 1991 for 2 years, since start of the biennial screening in 1989.

The four patient age groups showed a significant reduction in mean tumor size only in the screened women diagnosed with breast cancer aged 60−69 years from both 1991 and 1997/98, compared with the unscreened age groups from 1987 (Table 2).

To reach a stronger resolution, relative distributions within three tumor- size intervals (see Materials and Methods section) were analyzed in comparison between the two screened breast cancer patients from 1991 and 1997/98 versus the control sample from 1987 (Figures 1a and 1b). The screened breast cancer women aged 50−59 years in the 1991 sample revealed no significant deviation from the controls. They tended to decline for tumors>20 mm, but only those in the age group 60−69 showed a statistical significant reduction (Figure 1b). The 1997/88 sample showed significantly fewer tumors > 20 mm and significantly higher percentage of tumors ≤ 10 mm compared with controls in both screened ages (Figures 1a and 1b); this effect was stronger in the screened patients aged 60−69 years (Figure 1b).

In the 1991 sample, for screened patients aged 60 to 69 years, the percentage of tumors 10−20 mm increased significantly both related to the controls and to the 1997/98 sample (Figure 1b). This was a transient relative increase for the 1991 sample as tumors ≤ 10 mm have not yet been diagnosed to an increased degree, whereas the percentage of tumors >20mm had decreased significantly.

Tumor stage IIA T1c

The transient increase in tumors 10−20 mm in the 1991 sample is included in tumor Stage IIA T1c. In the 1991 sample, 164 women were diagnosed as Stage IIA T1 c− breast cancers, 87 women in Stage IIA T1c (53%) and 54 women were diagnosed as Stage IIB T2−3, including tumor size>20 mm (see Discussion).

Age and tumor size reflected in 2-dimensional plots

To show changes in tumor size, two-dimensional plots are shown in Figure 2. The control group from 1987 was compared with the 1997/98 sample in the tumor age interval ≥56 years. In the 1997/98 sample, the plot reflects the decline in tumor size for screened patients up to 65 years of age. The negative slope of the curve for the 1997/98 sample is statistically significant (Figure 2b). A similar comparison to the 1991

### Table 2: Tumor size in four age intervals in comparison of two screened cohorts against controls.

<table>
<thead>
<tr>
<th>Age in Years</th>
<th>1991 Size mm (n)</th>
<th>P</th>
<th>1987 Size mm (n)</th>
<th>P</th>
<th>1997/98 Size mm (n)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;50 (96)</td>
<td>19.4±12.6 (60)</td>
<td>ns</td>
<td>22.0±13.8 (98)</td>
<td>ns</td>
<td>22.8±13.5 (67)</td>
<td></td>
</tr>
<tr>
<td>50-59 (102)</td>
<td>19.3±13.6 (96)</td>
<td>ns</td>
<td>21.6±11.9 (79)</td>
<td>ns</td>
<td>18.5±12.9 (119)</td>
<td></td>
</tr>
<tr>
<td>60-69 (142)</td>
<td>17.7±13.8 (130)</td>
<td>&lt;0.001</td>
<td>23.5±13.3 (120)</td>
<td>p&lt;0.0005</td>
<td>15.4±12.4 (70)</td>
<td></td>
</tr>
<tr>
<td>≥70 (169)</td>
<td>21.8±11.5 (108)</td>
<td>ns</td>
<td>22.5±13.3 (103)</td>
<td>ns</td>
<td>20.4±14.2 (89)</td>
<td></td>
</tr>
</tbody>
</table>

Tumors from a control sample from 1987 and samples from 1991 and 1997/98 are sorted to four age intervals. The two screened age groups are flanked by those younger than 50 years of age and those older than 70 years, neither of which were invited to the screening. The results shows a significant reduction of mean tumor size related to screening only for women aged 60 to 69 years for both 1991 and 1997/98-samples.

Tumor size PI SSI ALMN+ Cyclin-A, Ki_67 Stage I Stage IIIB

The best screening effect was found in the 60–69 year age group in the 1997/98 sample, when the women had attended to screening tests about five times, and for whom samples were analyzed according to proliferation index (PI), SSI, lymph node metastasis, cyclin-A, Ki67 and tumor stage I and IIIB in relation to the two unscreened patients aged < 50 years and ≥ 70 years. For all parameters except ki67, the screened patients aged 60–69 years differed significantly from the younger unscreened group aged <50 years. However, the percentage of ki67^+ cells differed between the two unscreened age groups (<50 and ≥ 70 years; P<0.001) with significantly higher values for woman aged <50 years reflecting highly proliferative tumors among young women in contrast to more slower growing tumors in older women. For stage I and stage IIIB tumors a significant higher percentage of stage I tumors was found in the screened group aged 60–69 years as compared with the unscreened group < 50 years. Furthermore the tumor Stage IIIB group was significantly reduced in the screened sample versus the unscreened group <50 years. No significant differences emerged in any parameter over the older age group (Table 3). A similar investigation done for patients from 1991 showed the younger control group differed significantly only regarding lymph node metastasis (P<0.05) and reduction in tumor Stage IIIB in the 1991 sample (P<0.05; data not shown).

Reduction in breast cancer death rate

Screened woman diagnosed with breast cancer aged 60–69 years was studied with respect to death and survival rates versus the two unscreened breast cancer age groups over ten years of follow-up (Table 4). Screened groups from both 1991 and from 1997/98 show significantly lower mortality from breast cancer than the two unscreened populations. Despite higher mortality due to co-morbidity in the older age group, the death rate due to breast cancer was still significantly higher for older unscreened women than in both screened age groups. In a similar survey of the first age-decade screened patients sample was not significant (P = 0.32; not shown). In the control group no correlation was seen between tumor size and age (Figure 2a).

Seven parameters – proliferation index (PI), Stemline Scatter Index (SSI), axillary lymph node metastasis (ALNM); cyclin-A, Ki67 and tumor stage I and IIIB – were analyzed. All parameters but Ki67 significantly differed in the younger group. No significant difference appeared against the older patient group. Total number of patients per age interval is shown in the top line of the table. Because the parameters can have some missing values the n-values are also shown within the table. For cell cycle parameters the P-value is estimated using the mean values ± SD. For stage I and stage IIIB tumors the percentage in relation to the total patient number (n=64) is shown in the table. The P-value is estimated by comparing the percentages related to the n-values.

Table 3: Screened woman aged 60–69 years compared with the two unscreened patient groups younger than 50 years and older than 69 years.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>&lt; 50 years</th>
<th>50–69 years</th>
<th>≥ 70 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>PI P-value</td>
<td>0.01</td>
<td>0.01</td>
<td>0.01</td>
</tr>
<tr>
<td>SSI P-value</td>
<td>0.05</td>
<td>0.05</td>
<td>0.05</td>
</tr>
<tr>
<td>ALNM P-value</td>
<td>0.05</td>
<td>0.05</td>
<td>0.05</td>
</tr>
<tr>
<td>Cyclin-A P-value</td>
<td>0.05</td>
<td>0.05</td>
<td>0.05</td>
</tr>
<tr>
<td>Ki67 P-value</td>
<td>0.01</td>
<td>0.01</td>
<td>0.01</td>
</tr>
</tbody>
</table>

**Figure 1:** A) Relative distribution of tumor size over three increasing intervals for two mammography screened groups and controls of women aged 50–60 years are shown. Bars represent the percentage for size intervals. For tumors ≤10 mm, the 1997/98 sample increased significantly from the control sample of 1987 (P<0.01) and in the large group (>20 mm) the tumor size has decreased significantly (P<0.01). B) In the small size group (≤10 mm) the difference has increased further between the screened sample from 1997/98 and the control (P<0.01) and in the large group (>20 mm) the comparison is also stronger (P<0.001). In the middle size interval the 1991 sample differ significantly both to the control sample (P<0.05) and the 1997/98 sample (P<0.01). In the 1991 sample the large group (>20 mm) decreased significantly related to the control (P<0.001).

**Figure 2:** A) Two-dimensional scatter-plot is shown for the control 1987 sample analysis of age against tumors size. A widely dispersed plot is found and linear regression revealed a straight line (r = 0.07 p = 0.32 n = 231). B) In the 1997/98 sample, a two-dimensional scatter-plot based on the 1997/98 sample included unscreened subjects younger than 50 years, to demonstrate the screening effect. Analyzing age against tumor size showed a significant negative slope along with increasing age (r = -0.20 p<0.005 n = 223). The plot reveals the delayed effect in reduction of tumors size from the start of screening at the age of 50 years up to 65 years.

**Figure 3:** A) Two-dimensional scatter-plot is shown for the control 1987 sample analysis of age against tumors size. A widely dispersed plot is found and linear regression revealed a straight line (r = 0.07 p = 0.32 n = 231). B) In the 1997/98 sample, a two-dimensional scatter-plot based on the 1997/98 sample included unscreened subjects younger than 50 years, to demonstrate the screening effect. Analyzing age against tumor size showed a significant negative slope along with increasing age (r = -0.20 p<0.005 n = 223). The plot reveals the delayed effect in reduction of tumors size from the start of screening at the age of 50 years up to 65 years.

**Figure 4:** A) Two-dimensional scatter-plot is shown for the control 1987 sample analysis of age against tumors size. A widely dispersed plot is found and linear regression revealed a straight line (r = 0.07 p = 0.32 n = 231). B) In the 1997/98 sample, a two-dimensional scatter-plot based on the 1997/98 sample included unscreened subjects younger than 50 years, to demonstrate the screening effect. Analyzing age against tumor size showed a significant negative slope along with increasing age (r = -0.20 p<0.005 n = 223). The plot reveals the delayed effect in reduction of tumors size from the start of screening at the age of 50 years up to 65 years.

**Figure 5:** A) Two-dimensional scatter-plot is shown for the control 1987 sample analysis of age against tumors size. A widely dispersed plot is found and linear regression revealed a straight line (r = 0.07 p = 0.32 n = 231). B) In the 1997/98 sample, a two-dimensional scatter-plot based on the 1997/98 sample included unscreened subjects younger than 50 years, to demonstrate the screening effect. Analyzing age against tumor size showed a significant negative slope along with increasing age (r = -0.20 p<0.005 n = 223). The plot reveals the delayed effect in reduction of tumors size from the start of screening at the age of 50 years up to 65 years.
close to significance \((P<0.07)\) indicating a lingering post-screening effect. The percentage tumors 10–20 mm for 1991 continues to be significantly larger than the control (compare Fig 1b). For tumors ≤ 10 mm, another post-screening effect was seen. The high percentage of small tumors (45.6%) in the 1997/98 sample for screened patients aged 60-69 years fell to 21.8% in the first post-screened age group \((P<0.01);\) Figure 3a; see Discussion). Only the small tumors ≤ 10 mm approached control levels immediately after the end of screening; a post-screening effect was seen for the other two size intervals. In the control sample a slight reduction in tumor size 10-20 mm was seen but compared to the controls aged 50-69 (Figure 1b) no significant difference was found. The percentages patients aged ≥ 70 years in the three samples were 1987(27%), 1991 (33.2%) and 1997/98 (25%). The 1991 sample increased significantly versus the controls from 1987 \((P<0.05)\) and the sample 1997/98 \((P<0.01)\) indicating a transient increase of post-screened patients in a shorter follow-up in 1991 before the screened patient group aged 50-69 years increases in percentage of whole samples after a longer follow-up: 1987 (48.5%), 1991 (47.9%) and 1997/98 (54.8%) \((p<0.05)\)

### Table 4: Breast cancer death rate and death due to co-morbidity for screened women aged 60-69 years.

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>&lt; 50</th>
<th>60–69</th>
<th>≥70</th>
</tr>
</thead>
<tbody>
<tr>
<td>1991</td>
<td>96 (100%)</td>
<td>142 (100%)</td>
<td>169 (100%)</td>
</tr>
<tr>
<td>Death from BC</td>
<td>34 (35.4%)</td>
<td>22 (15.5%)</td>
<td>43 (25.4%)</td>
</tr>
<tr>
<td>Death from other causes</td>
<td>2 (2.1%)</td>
<td>16 (11.3%)</td>
<td>55 (32.5%)</td>
</tr>
<tr>
<td>Alive</td>
<td>60 (62.5%)</td>
<td>104 (73.2%)</td>
<td>71 (42.1%)</td>
</tr>
<tr>
<td>1997/98</td>
<td>64 (100%)</td>
<td>115 (100%)</td>
<td>88 (100%)</td>
</tr>
<tr>
<td>Dead in BC</td>
<td>16 (25%)</td>
<td>5 (7.4%)</td>
<td>16 (21.6%)</td>
</tr>
<tr>
<td>Dead other causes</td>
<td>2 (3.1%)</td>
<td>9 (13.2%)</td>
<td>34 (38.8%)</td>
</tr>
<tr>
<td>Alive</td>
<td>46 (71.9%)</td>
<td>54 (79.4%)</td>
<td>38 (30.8%)</td>
</tr>
</tbody>
</table>

Screened women aged 60-69 years were analyzed for both 1991 and 1997/98 samples for death rates from breast cancer and from other causes. Results were compared with two unscreened age groups, i.e. those younger than 50 years of age and older than 70 years. The 1991 and 1997/98 samples showed significant reductions in breast cancer death rates compared with both the younger \((P < 0.01)\) and the older \((P < 0.01)\) unscreened patient groups, notwithstanding the co-morbidities of the older patients. The percentage of patients still alive with co-morbidities was, as expected, significantly less in the older patients.

### The oldest age group

In the age group ≥ 79 years, representing about 10% in each sample, the control tumors from 1987 for the first time shows a significant change in tumor-size distribution reflected in the bars in Figure 3b. The percentage of control-group tumors ≥ 20 mm was reduced to 35.5% as compared with control-group tumors 10–20 mm (61.3%; \(P<0.02)\). These two tumor size intervals in the control sample appeared on an equal level ~40%, for women aged 50–79 years (Figures 1a, 1b and 3b). The high percentage control tumors in the 10–20 mm interval differed significantly from the 1997/98 samples (27.6%), and the corresponding tumor size interval from 1991 (37.3%; Figure 3b). There is no significant difference found when all three sample in the size interval ≥ 20 mm are compared (Figure 3b) despite the tending increase in both study samples, probably due to the smaller samples in this age group. Interestingly, tumors ≤ 10 mm were significantly increased among patients in the 1997/98 sample compared to the controls (see Discussion).

### Discussion

Data from the initial period of mammography screening indicate a lag time before significant positive effect emerged, as reflected in reduced tumor size at diagnosis, decreased genomic instability, lower proliferation activity, diminished involvement of lymph node metastasis reduced death rate due to breast cancer. These benefits showed a clear change first for women aged 60-69 years, when they had attended optimal screening test in the biennial schedule used (Tables 2 and 3). Women aged 50-61 years in 1989 at the start of screening had an optimal chance to be involved in five screening tests, when included in the 1997/98 sample collection at 58-69 years old. In 1991, women aged 55 to 67 years might have the best chance of getting the second mammographic screening that year.

Screening for breast tumors focuses on tumor size. The results show clearly that the other investigated parameters are strongly linked to tumor size. Parameters that reflect growth potentials with cells in S- and G2-phase (PI) and cyclin-A, followed the same pattern to decline significantly for screened patients aged 60-69 years, compared with the unscreened women with breast cancer aged <50 years (Table 3). For ki67, which indicates cell growth in any cell cycle phase, no
differences were found. This implies that tumor cells are, as expected, growing in both screened and unscreened patient groups; however, the difference in PI and cyclin-A levels indicate decreased S-phase entry in the smaller diagnosed tumors, which were detected in higher frequency after lengthy screening. For tumor stage I and II is to significantly increased stage I and decreased stage II was found in the screened group aged 60-69 years (Table 3).

Death rate due to breast cancer was significantly diminished in a 10 years of follow up for patients aged 60-69 years compared to unscreened patients aged <50 years in both 1991 and 1997/98 samples, as was true versus patients aged ≥ 70 years (Table 4). Notably, a significant higher death rate due to breast cancer appeared in the older patient group despite the higher death rate from other causes [21].

The change in tumor-size distribution in the three size intervals analyzed reflects the impact of mammography screening over time on tumor size (Figures 1 and 3). During the initial introduction period, the frequency of large tumors > 20 mm was slightly reduced for women 50-59 years in the 1991 sample: However, for women aged 60-69 years, the sample showed a statistically significant reduced percentage of these larger tumors, but still no increase of small tumors ≤ 10 mm (Figure 1a-b). In the 1997/98 sample, included longer screening time at the sample collection, a significant increase in the detection of tumors ≤ 10 mm was found for women aged 50-59 years as well as a significant reduced frequency of large tumors >20 mm (Figure 1a). This trend was more pronounced in women aged 60-69 years (Figure 1b), who attended more screening tests.

Increased incidence of reported breast cancer due to mammography screening and an expected reduced incidence among elderly non-screened women has been an controversial objective [1,2,12,13,15,17]. The idea of detecting tumors by screening that might have regressed spontaneously implies that screening in its early phase harvests many larger tumors, but still no increase of small tumors ≤ 10 mm (Figures 1 and 2). During the initial introduction period, the frequency of large tumors > 20 mm was slightly reduced for women 50-59 years in the 1991 sample: However, for women aged 60-69 years, the sample showed a statistically significant reduced percentage of these larger tumors, but still no increase of small tumors ≤ 10 mm (Figure 1a-b). In the 1997/98 sample, included longer screening time at the sample collection, a significant increase in the detection of tumors ≤ 10 mm was found for women aged 50-59 years as well as a significant reduced frequency of large tumors >20 mm (Figure 1a). This trend was more pronounced in women aged 60-69 years (Figure 1b), who attended more screening tests.

The increased transient Stage II+ found during the first years after introduction of screening [14] was interpreted as a candidate for spontaneously tumor regression. That result might correspond to the transient increase in Stage IIB T1c found in the 1991 sample, during the introduction period of screening, due to the redistribution within the three tumor size intervals (Figure 1b).

A post-screening effect was found in this report. Both investigated populations from 1991 and 1997/98 had a decreased percentage of tumors >20 mm for women aged 70-79 years as a lingering effect after screening. Between screened women aged 60-69 years and the first post-screened group aged 70-79 years the tumors ≤ 10 mm in the 1997/98 sample deceased significantly from 45.5% to 21.8%-i.e. back to the control levels (Figure 3a). This decline in tumors ≤ 10 mm after the screening period might be one part of an explanation for not observing an increased incidence of breast cancer cases after the end of the screening period.

The bars of the control sample from 1987 in Figures 1a and 1b did not change in size distribution at all between the three tumor-size intervals for women aged 50-69 years. A slight but not significant reduction in intermediate tumor size for controls aged 70-79 years was seen which indicates that breast self-examination (BSE) and clinical breast examination (CBE) did not change the distribution of control tumor size sub-groups in the age interval 50-79 years. However, it was observed in the oldest age group ≥ 79 years.

In the oldest population, control size distribution changed (Figure 3b). The percentage of control tumors > 20 mm decreased for women aged ≥ 79 years, while control tumors 10−20 mm increased significantly (Figure 3b). It is similar to the 1991 sample and the tumor-size distribution for screened patients aged 60-69 years (Fig.1b) reflecting an early effect of screening before the increase in tumor size ≤ 10 mm appears. BSE and CBE may affect control tumor size distribution at diagnosis at this high age, thus reducing the percentage of tumors > 20 mm. The increase in the percentage of tumors ≤ 10 mm at this high age, found in the 1997/98 sample, might be a late compensating post-screening effect, when small tumors re-appear after being diagnosed in high frequency during screening. At this high age, they have reached a now-palpable size and are more easily detected in aging breast tissues with decreased fat involvement (Figure 3b).

Conclusions

These results analyze screening effect on three tumor-size intervals 2 and 8 years after introduction of mammographic screening. They show that during the first period mainly large tumor 20 mm are diagnosed and as screening proceeds, discovery of smaller tumors ≤ 10 mm increases. These results imply that diagnosis of small but clinically significant tumors through screening requires long-term follow-up, and might not be most effective the first years after screening is introduced. The method used in this report reveals a post-screening effect of drastic reducing in the frequency of small tumors ≤ 10 mm and still diagnosing tumors >20 mm at rates smaller than those of controls, as a lingering post-screening effect in the first age decade after screening. Further research might address whether the delayed effect of screening in reducing tumor size is related to the fact that more and earlier X-rays facilitate detection of change by allowing comparison of previous images. Improvement of screening over time implies that longer screening periods give stronger screening benefits. Increasing the screening period in Sweden from 40 years to 74 years has reduced the mean tumor size to 17 mm. The question of overdiagnosis is an important issue that needs further studies to reach consensus.

Acknowledgements

Fruitful discussions have been held with prof Edward Azavedo, Radiology Department, Section of Mammography, Karolinska Hospital and Karolinska Institutet, Stockholm, Sweden. Edanz Group Ltd did language editing. Support given from Karolinska Institutet Funds.

Conflict of Interest

This report does not include the use of any commercial products with connections to the author. The staining techniques used have been established since several decades. There is no way to get economical benefits from a publication of this article

References

1. Jørgensen KJ, Gøtzsche PC (2009) Overdiagnosis in publicly organised...


